drug · antibody
DUPIXENT
updated 6mo ago/ dew-PIL-oo-mab /
by $REGN REGENERON PHARMACEUTICALS, INC.🔗 ChEMBL
community read0 votes
🐶 often sniffed alongside
top 7Antibody drug with a maximum clinical stage of Approval (across all indications), with 8 approved and 30 investigational indications.
targets
Interleukin-4 receptor subunit alpha
all catalysts(0)
nothing on the calendar yet
Trials studying DUPIXENT
- —A Long-term Data Collection Study of Participants in France Aged 6 Years Old or More With Atopic Dermatitis Receiving Dupilumab
- phase4Ethnic Differences in Mechanisms of Action of Dupilumab
- phase3A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines
- phase1Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy Participants
- phase3Efficacy and Safety of Subcutaneous Dupilumab for the Treatment of Adult Participants With Chronic Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)
- phase1An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis
- phase3A Study Assessing the Effect of Dupilumab on Inducing Clinical Remission in Asthma
- —Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
News(10)
- Sanofi gains FDA clearance for Gaucher disease pillThe approval culminates a winding development journey for Infilbray, and provides Sanofi with a new source of income ahead of Dupixent’s looming patent expiration.biopharma_dive · 3h ago
- With FDA nod, Regeneron brings an RNAi drug to autoimmune diseaseThe product of a collaboration with Alnylam, Livsayis is now Regeneron’s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.biopharma_dive · 5h ago
- Seawolf surfaces with $100M, $1.2B Sanofi pact for redosable DNA medicinesBacked by Novartis’ venture arm, Eli Lilly and CRISPR Therapeutics, Seawolf is advancing its nonviral DNA delivery platform while inking a pact with Sanofi.biospace · 3d ago
- Regeneron’s POTS antibody curbs heart rate spikes, teeing up Phase 3 trialRegeneron’s mid-stage success in postural orthostatic tachycardia syndrome has the company gearing up to launch a Phase 3 study in the first half of 2027.biospace · 6d ago
- STAT+: Pharmalittle: We’re reading about India’s new manufacturing rules, clinical trials in China, and moreIndia proposed rules requiring regulators to immediately suspend manufacturing licenses for drugs that fail quality standards in government testingstat · 14d ago
- Sanofi stops development of Nurix-partnered immune drugThe decision sparked a sell-off in Nurix shares as well as analyst debate about the prospects of drugs designed to degrade a tough-to-reach protein called STAT6.biopharma_dive · 15d ago
- Sanofi’s axing of Nurix STAT6 program ‘not a target-related issue’Sanofi has discontinued an early-stage STAT6 degrader program licensed from Nurix Therapeutics, a decision analysts say is related to the asset itself or Sanofi’s strategic reprioritization rather…biospace · 15d ago
- STAT+: Ultragenyx cuts staff after another study failsUltragenyx announced that it's laying off about 20% of its staff as it ends development of two rare disease drugs.stat · 15d ago
- STAT+: Pharmalittle: We’re reading about CVS plans to split up, FDA inspections in India and China and moreThe Trump administration will survey key components of pharmaceutical production in order to identify domestic supply chain vulnerabilities.stat · 15d ago
- STAT+: Former Madrigal Pharmaceuticals executive alleges coverup of safety issues tied to its drugA top former executive at Madrigal Pharmaceuticals has filed a lawsuit in federal court alleging a coverup of drug safety issues.stat · 15d ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that